Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study

por Chatham, W. Winn, Furie, Richard, Saxena, Amit, Brohawn, Philip, Schwetje, Erik, Abreu, Gabriel, Tummala, Raj
Publicado 2021

Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials

por Stull, Donald, O’Quinn, Sean, Williams, Betsy, Bean, Stephanie, Schwetje, Erik, Abreu, Gabriel, Tummala, Raj
Publicado 2022

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial

por Jayne, David, Rovin, Brad, Mysler, Eduardo, Furie, Richard, Houssiau, Frédéric, Trasieva, Teodora, Knagenhjelm, Jacob, Schwetje, Erik, Tang, Weifeng, Tummala, Raj, Lindholm, Catharina
Publicado 2023

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

por Jayne, David, Rovin, Brad, Mysler, Eduardo F, Furie, Richard A, Houssiau, Frederic A, Trasieva, Teodora, Knagenhjelm, Jacob, Schwetje, Erik, Chia, Yen Lin, Tummala, Raj, Lindholm, Catharina
Publicado 2022